BioMedNewsBreaks – ROTH’s Healthcare Opportunities Conference to Showcase ~25 Carefully Selected Companies

ROTH Capital Partners, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Inaugural Healthcare Opportunities Conference in New York City on Oct. 6, 2022. The conference will feature approximately 25 public healthcare companies that have been selected by ROTH’s research analysts and provide C-level executives the opportunity to closely interact with pre-qualified institutional investors and healthcare industry professionals. The event will have a multiple sub-sector focus with participating companies operating in biotechnology, pharmaceuticals, medical technologies, oncology and mental health therapeutics. “Most healthcare conferences are skewed toward companies whose market capitalizations are quite large,” said Tony Butler, Ph.D., managing director, senior research analyst and head of biotechnology research. “Investments may be crowded. Our conference offers opportunities for investors to possibly generate higher alpha within their portfolios.”

To view the full press release, visit https://ibn.fm/sQiI3

About ROTH Capital Partners LLC

ROTH Capital Partners is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, California, ROTH is privately held and owned by its employees and maintains offices throughout the U.S. For more information on ROTH, please visit www.ROTH.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Completes Reverse Stock Split to Support Growth Plans

HealthLynked (OTCQB: HLYK) has completed a reverse stock split as part of its strategy to…

3 days ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Data Demonstrating Two-Year Stability of ThermoVax Ebolavirus Vaccines

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the publication of…

4 days ago

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Preclinical Data Showing CNM-Au8 Improves Cellular Health in Parkinson’s Disease Model 

Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc., announced new preclinical data…

4 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights CEO Dr. Vuong Trieu’s Impact and Clinical Pipeline Progress

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments, provided an…

4 days ago

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Subsidiary Publishes Landmark Primer on Oncology Real-World Evidence

Fifty 1 Labs (OTC: FITY) through its subsidiary Fifty1 AI Labs, announced the publication of…

4 days ago

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) CEO Featured on IBN’s BioMedWire Podcast

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing the IzoView Breast…

4 days ago